Karyopharm Therapeutics Inc (KPTI) - Total Liabilities

Latest as of June 2026: $441.49 Million USD

Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has total liabilities worth $441.49 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Karyopharm Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Karyopharm Therapeutics Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Karyopharm Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Karyopharm Therapeutics Inc assets under control.

Karyopharm Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Karyopharm Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Strategic Investments A/S CO:STRINV	Denmark	Dkr84.61 Million
Inhwa Precision Co. Ltd KQ:101930	Korea	₩131.24 Billion
Namyang Dairy Products Co Ltd Peffered Series 1 KO:003925	Korea	₩146.42 Billion
Bo Lak KO:002760	Korea	₩9.54 Billion
Estoril Sol SGPS SA LS:ESON	Portugal	€205.95 Million
Indah Prakasa Sentosa PT Tbk JK:INPS	Indonesia	Rp283.96 Billion
BIT Computer Co. Ltd KQ:032850	Korea	₩9.91 Billion
Vanfund Urban Investment & Development Co Ltd SHE:000638	China	CN¥153.23 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Karyopharm Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See KPTI equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.79	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.34	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.97	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Karyopharm Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Karyopharm Therapeutics Inc (2011–2025)

The table below shows the annual total liabilities of Karyopharm Therapeutics Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	$401.34 Million	+14.53%
2024-12-31	$350.44 Million	-6.96%
2023-12-31	$376.64 Million	+0.48%
2022-12-31	$374.83 Million	-2.64%
2021-12-31	$384.98 Million	+46.66%
2020-12-31	$262.50 Million	+7.06%
2019-12-31	$245.19 Million	+55.16%
2018-12-31	$158.02 Million	+210.88%
2017-12-31	$50.83 Million	+180.18%
2016-12-31	$18.14 Million	+6.23%
2015-12-31	$17.08 Million	+26.10%
2014-12-31	$13.54 Million	+311.39%
2013-12-31	$3.29 Million	-88.72%
2012-12-31	$29.19 Million	+46.86%
2011-12-31	$19.88 Million	--

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology

Market Cap

$40.57 Million

Market Cap Rank

#22781 Global

#5004 in USA

Share Price

$1.79

Change (1 day)

+5.29%

52-Week Range

$1.54 - $10.67

All Time High

$27.72